Quick Facts
Plain-English Summary
NAD+ (nicotinamide adenine dinucleotide) is one of the most fundamental molecules in human biochemistry. It functions as an electron carrier in the central metabolic pathways — glycolysis, the tricarboxylic acid (TCA) cycle, and oxidative phosphorylation — and as a required substrate for a class of enzymes called sirtuins (SIRT1–7) that regulate gene expression, DNA repair, and inflammation. Without NAD+, cells cannot generate ATP, repair DNA efficiently, or maintain metabolic homeostasis.
A key observation driving longevity research is that NAD+ levels decline substantially with age. Studies in human tissue have found approximately 50% lower NAD+ concentrations by age 60 in some organs compared to younger adults. Whether this decline is a cause or consequence of aging-related dysfunction is an active scientific question; the "NAD+ restoration hypothesis" holds that supplementing NAD+ or its precursors could slow or partially reverse aspects of cellular aging.
The most mechanistically significant downstream targets of NAD+ in longevity research are the sirtuin deacetylases. Sirtuin activity is directly NAD+-dependent — they cannot function without it. Sirtuins regulate histone deacetylation (gene silencing), mitochondrial biogenesis, and inflammatory signalling. PARP-1, another NAD+-consuming enzyme, uses NAD+ as a substrate during DNA strand-break repair; genotoxic stress causes rapid NAD+ depletion through this pathway. Both mechanisms are well-established in peer-reviewed literature.
Unlike most compounds in this catalogue, NAD+ has a substantial and well-characterised biochemical literature spanning decades. The uncertainty lies not in its basic biology — which is firmly established — but in whether exogenous supplementation (particularly via IV or oral routes) achieves meaningful and sustained tissue-level increases, and whether those increases translate to the clinical outcomes promoted in longevity and wellness markets.
Clinically, IV NAD+ has its longest history in addiction medicine, specifically the Waismann method for opioid and alcohol withdrawal, where high-dose IV infusions are used to manage acute withdrawal symptoms. Pilot human studies have reported improvements in fatigue and cognitive function. Oral precursors — NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — have been evaluated in human trials with growing evidence of elevating blood NAD+ levels, though whether elevated circulating NAD+ translates to tissue-level changes and clinical endpoints remains an open question as of 2026.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Mouse vascular aging (NMN) | Sinclair lab (Nature 2013): NMN supplementation reversed age-related vascular dysfunction in old mice, restoring endurance capacity. Muscle capillary density and blood flow improved to levels resembling younger animals. Human relevance under study. Das A et al. Cell 2018 ↗ | Preclinical |
| Mouse lifespan extension | NMN and NR supplementation extended median lifespan and healthspan in multiple mouse strains. Improvements in glucose metabolism, energy expenditure, and physical activity observed. Lifespan extension in mice does not predict equivalent human longevity effects. Gomes AP et al. Cell 2013 ↗ | Preclinical |
| Mouse DNA repair (SIRT1/PARP) | NAD+ repletion restored SIRT1-mediated DNA repair activity in aged mice, reversing epigenetic changes associated with aging. PARP-1 competition for NAD+ is central to the proposed mechanism of sirtuin suppression in aging. Gomes AP et al. Cell 2013 ↗ | Preclinical |
| Mouse neurodegeneration models | NAD+ precursor supplementation attenuated neurodegeneration in Alzheimer's and Parkinson's mouse models. Improved cognitive performance and reduced amyloid pathology in some models. No human clinical trials for neurodegeneration completed as of 2026. Lautrup S et al. Cell Metab 2019 ↗ | Preclinical |
| Rodent metabolic syndrome models | NMN improved insulin sensitivity, reduced hepatic fat accumulation, and improved mitochondrial function in diet-induced obese mice. These findings informed early NMN human trials in metabolic populations. Yoshino J et al. Cell Metab 2011 ↗ | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| IV NAD+ — Addiction / Withdrawal (Waismann Method) | Patients with opioid, alcohol, or stimulant dependence; high-dose IV NAD+ infusion over 4–10 days at licensed clinics (South Africa, USA) | — | Observational |
| NMN — Insulin Sensitivity (Yoshino et al.) | 25 postmenopausal women with prediabetes; 10 weeks NMN supplementation (250 mg/day) vs. placebo; RCT | — | RCT · Published |
| NR — Blood NAD+ Elevation (Multiple) | Healthy adults across multiple Phase I/II trials; doses 250–2000 mg/day NR orally for 6–12 weeks | — | Biomarker Only |
| NMN — Fatigue & Muscle Function (Japan) | Healthy older adults; 250 mg/day NMN for 12 weeks; placebo-controlled | — | Pilot RCT |
| Longevity / Lifespan Extension | No human trials of any design | — | No Data |
NAD+ has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
Oral NMN and NR: well-tolerated in clinical trials at doses up to 2000 mg/day with no serious adverse events reported. IV NAD+ in addiction medicine settings has a reasonable tolerability record across thousands of clinical administrations, though systematic safety data is limited to observational sources.
IV NAD+ commonly causes transient reactions during infusion: chest tightness, flushing, nausea, palpitations, and a characteristic "pressure" sensation in the head or chest. These are rate-dependent — slower infusion rates substantially reduce incidence. Reactions are generally self-limiting but can be alarming to patients unfamiliar with them.
- Mild nausea at higher oral doses
- Flushing (less common than with niacin)
- Transient headache
- GI discomfort in some users
- No pharmacovigilance database exists for NMN/NR
- Potential for CD38-driven NAD+ re-depletion after supplementation
- Unknown long-term effects of sustained NAD+ elevation in cancer biology (PARP implications)
- Interactions with existing PARP inhibitor medications (e.g., olaparib)
- Not established in pregnancy, paediatric populations, or active malignancy
NAD+ is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of NAD+ for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
The core biochemistry here is genuinely solid — NAD+ is not a fringe compound, it's one of the most studied molecules in cellular biology. The frustrating part is that most of the clinical noise conflates three very different things: IV NAD+ for addiction (which has a real, if poorly controlled, evidence base), oral NMN/NR for metabolic effects (growing RCT data, modest effect sizes), and longevity claims (no human data, extrapolated from mice). The internet treats these as one story. They're three different conversations.
Exactly right. The Yoshino Science paper is actually well-designed — it's a real RCT with a real endpoint (insulin-stimulated glucose uptake in muscle), not just a blood NAD+ biomarker study. The effect is genuine. The problem is that gets cited as proof for completely different claims the study never measured.
Something that gets underweighted in popular discussion: CD38 upregulation with age may be the dominant driver of NAD+ decline, not just PARP competition. CD38 is induced by chronic inflammation ("inflammaging"), which means the NAD+ depletion problem in old tissue may be partially downstream of systemic immune dysregulation. Supplementing NAD+ without addressing the CD38 elevation might be analogous to topping up a leaking tank. The real intervention might be CD38 inhibition (apigenin, quercetin, etc.) combined with NAD+ precursors.
I've sat through two IV NAD+ infusions in a clinical context — one for research, one personal. The infusion reaction is real and disconcerting if you're not warned. Chest pressure, flushing, a feeling of mild panic. Not dangerous at a therapeutic rate, but the clinical protocols in wellness clinics vary enormously. The absence of any standardised dosing, infusion rate, or monitoring protocol in this market is genuinely concerning. This is not a reason not to use it, but it's a reason to be very selective about the setting.
The infusion rate issue is a legitimate clinical concern. The reactions are rate-dependent — slower delivery largely eliminates them. A 500 mg dose pushed over 30 minutes is a completely different experience from 500 mg over 3 hours. Any clinic not individualising the rate is cutting corners.
NAD+ sits in an unusual epistemic position compared to most compounds in this space: the basic science is excellent, the animal data is excellent, the preliminary human data is credible (especially the Yoshino RCT), and the longevity claims are completely unsupported. Most of the wellness market is selling the last category while hiding behind the credibility of the first three. If you want to use NMN for insulin sensitivity and metabolic health in mid-life — that has actual human data behind it. If you want it to extend your lifespan — you are a mouse in an experiment that hasn't happened yet.